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Abstract
Background: Schizophrenia is a neurodevelopmental disorder with onset early in adulthood. Disrupted-In-Schizophrenia-1
(DISC1) is a susceptibility gene for schizophrenia and other psychiatric disorders. Disc1-L100P mutant mice show behaviors
relevant to schizophrenia at 12 weeks, but not at 8 weeks of age, and may be useful for investigating the onset of
schizophrenia in early adulthood.
Methods: We investigated whether early valproic acid treatment would prevent behavioral, cellular and gene expression
abnormalities in Disc1-L100P mutants.
Results: Valproic acid prevented hyperactivity and deficits in prepulse inhibition and latent inhibition in Disc1-L100P mice.
Genome-wide transcription profiling identified Lcn2 (lipocalin2) transcripts as being elevated by the Disc1 mutation and
corrected by valproate. Disc1-L100P mice also had increased glial cell numbers in the subventricular zone, which was
normalized by valproate. Genetic deletion of Lcn2 normalized glial cell numbers and behavior in Disc1-L100P mutants.
Conclusions: Pharmacological treatments are a feasible way of preventing abnormal behaviour in a genetic model of
schizophrenia. Lcn2 is a potential novel drug target for early intervention in schizophrenia.
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Introduction
Schizophrenia is a neurodevelopmental disorder in which
genetic and environmental factors disturb brain development,
but the symptoms typically do not emerge until early adulthood
[1]. Disrupted-In-Schizophrenia-1(DISC1) is a risk gene for
schizophrenia and other mental illnesses, [2] encoding a scaffold
protein [3] that is critical for adult neurogenesis [4,5], neuronal
migration, dendrite maturation and synaptogenesis [6,7]. Better
understanding of the molecular mechanisms by which DISC1
variation alters neurodevelopment could lead to new treatment
targets for neuropsychiatric illness.
There are a number of mouse models with DISC1 mutations or
altered DISC1 expression [2], demonstrating that the neurobio-
logical and behavioral effects of DISC1 perturbation are time
dependent [8,9]. For example, transient expression of the DISC1
C-terminus on postnatal day 7 had effects not seen when
expression was induced in adulthood [8]. The timing of expression
of truncated DISC1 also has distinct behavioral effects [9].
Although behavioral impairments in various mutant DISC1 mouse
models have been observed in adult mice [10], the behavior of
these mice as young adults has not yet been investigated.
We previously characterized Disc1-L100P mice generated by
ENU mutagenesis [11]. Disc1-L100P mutants have disrupted pre-
pulse inhibition (PPI), latent inhibition (LI), and working memory,
in addition to hyperactivity. These schizophrenia endophenotypes
[12], were corrected by antipsychotic treatment [11,13]. Disc1-
L100P mice are more sensitive to amphetamine, and have more
D2 receptors in the striatum [13]. The Disc1-L100P mutation also
reduced interactions between DISC1 and phosphodiesterase 4B
(PDE4B) [11], and with glycogen synthase kinase-3 (GSK-3) [14].
Both rolipram (a PDE4B inhibitor) and TDZD-8 (a GSK-3
inhibitor) normalized behavior in Disc1-L100P mutants [11,14].
Furthermore, the Disc1-L100P mutation impaired cortical de-
velopment and cellular architecture [7], and affects expression of
synaptic modulators neurexin 1 and 3 (Nrxn1/3) at critical
developmental periods [15].
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Because the Disc1-L100P mouse has many features consistent
with schizophrenia, we sought to determine whether there was also
an early adult onset of behavioral abnormalities. We found the
behavior of 8 week-old mice to be normal [11,13,14], so we
hypothesized that early intervention could rectify neurodevelop-
ment and prevent abnormal behaviors emerging later in adult-
hood (12 weeks of age). Valproic acid (2-propylpentanoic acid)
[16], given to Disc1-L100P mutant mice in early adulthood,
prevented the emergence of schizophrenia-related behaviors later
on. We profiled gene transcription in brain and identified higher
Lcn2 (Lipocalin2) transcript levels in Disc1-L100P mice that were
normalized by valproic acid. Lcn2 is co-expressed with glial
fibrillary acidic protein (GFAP) in brain, and the increased
number of glial cells in Disc1-L100P mutants was corrected by
valproic acid. Genetic ablation of Lcn2 [17] normalized both
behavior and glial cell numbers in Disc1-L100P mutants. Our
work demonstrates that pharmacological intervention can prevent
the onset of schizophrenia-related behaviors and suggests Lcn2 as
a novel drug target for preventive treatment of schizophrenia.
Materials and Methods
Ethics Statement
All animal procedures were approved by the Toronto Centre
for Phenogenomics (TCP) Animal Care Committee (AUP number
12-0025a-H) and followed the requirements of the Province of
Ontario Animals for Research Act and the Canadian Council on
Animal Care.
Animals
Disc1-L100P homozygous mutants were generated as previously
described [11], and backcrossed with C57BL/6 mice for 10–14
generations. Experiments were performed with 8, 12 and 15 week-
old animals in sex-balanced groups. Lcn2-KO mice were back-
crossed with C57BL/6J for 10 generations [18] and bred with
Figure 1. Disc1-L100P mutant mice show schizophrenia-related behavior at 12 but not 8 weeks of age. (a) 12 week-old Disc1-L100P
mutant mice were hyperactive (n = 7219 per group) as measured by total distance traveled during 30 minutes in the open field [F1,22 = 4.5, p,0.05
effect of genotype; F1,22 = 17.1, p,0.001 effect of age; F1,22 = 9.4, p,0.01 gene6 age interaction]. (b) 12 week-old Disc1-L100P mutant mice have
impaired PPI (n = 7210 per group) [F1,49 = 58.8, p,0.001 effect of genotype; F1,49 = 4.97, p#0.05 age; F2,98 = 150.2, p,0.001 prepulse intensity;
F1,49 = 9.3, p,0.01 gene6 age interaction]. (c) 12 week-old Disc1-L100P mutant mice have reduced Acoustic Startle Response (ASR) (n = 7210 per
group) [F1,49 = 19.9, p,0.001 genotype; F1,49 = 8.6, p,0.01 gene6 age interactions]. *p,0.05, **p,0.01, ***p,0.001 in comparison with WT mice
within each age group. (d) 12 week-old Disc1-L100P mutant mice have disrupted LI (n = 628 per group) [F1,47 = 19.1, p,0.001 genotype; F1,47 = 15.4,
p,0.001 age; F1,47 = 49.1 p,0.001 effect of pre-exposure; F1,47 = 4.5, p,0.05 gene6age6pre-exposure interactions]. The eight experimental groups
did not differ in A periods (all p.0.05, overall mean A period= 6.8 sec). ***p,0.001 non-pre-exposed (NPE) in comparison with pre-exposed (PE)
animals to the conditioned stimulus (CS) within each genotype and age group. See also Supplementary Table S1.
doi:10.1371/journal.pone.0051562.g001
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Disc1-L100P homozygous mice to obtain WT, heterozygous and
homozygous Disc1-L100P mice having two, one or no copies of
Lcn2. Groups of 3–5 same-sex littermates were housed in filtered
polycarbonate cages at 2161uC, lights on 0700 h-1900 h and
humidity at 50–60%. Animals were fed sterile Purina mouse chow
and water ad libitum, except in the latent inhibition experiments.
Behavioral experiments were conducted blind to genotype and
drug treatment.
Behavioral Assays
Locomotor activity. Monitored for 30 minutes in a directly
illuminated (600 Lux) clear Perspex chamber
(42 cm642 cm630 cm; Accuscan Instruments Inc, Ohio, USA)
by interruptions of 16 horizontal and 16 vertical infrared beam
sensors 2.5 cm apart.
Pre-pulse Inhibition (PPI) of Acoustic Startle Response
(ASR). Measured as previously described [11]. Five types of
trials were used: (i) Pulse alone - single white noise burst (120 dB
40 ms); (ii) Prepulse+pulse (PP69P, PP73P, PP81P) – noise
prepulse (20 ms at 69, 73, or 81 dB) followed by startle pulse
(120 dB 40 ms) 100 ms after the prepulse onset; (iii) No-stimulus -
background noise only (65 dB). Sessions were structured as
follows: (i) 15-minute acclimation at background noise level; (ii)
five Pulse trials; (iii) ten blocks each containing all five trials (Pulse,
PP69P, PP73P, PP81P, No-stimulus) in pseudorandom order; (iv)
five Pulse trials. The force intensity for each trial was recorded as
the startle level. The percentage PPI induced by each prepulse
intensity was calculated as [1-(startle amplitude on prepulse trial)/
(startle amplitude on pulse alone)]*100%.
Latent Inhibition (LI). Assessed as previously described
[11]. Mice were trained to drink in the experimental chamber for
5 days, 15 minutes per day. The LI procedure consisted of Pre-
exposure, Conditioning, Lick Retraining and Test sessions. Pre-exposure:
The pre-exposed (PE) mice received 40 white noise presentations
(60 s inter-stimulus interval). The non-pre-exposed (NPE) mice
were confined to the chamber for the same time without receiving
the stimuli. Conditioning: All mice received fear conditioning to the
noise stimulus. Two noise-shock pairings were used (10 s 85 dB
white noise; 1 s 0.37 mA shock). Test: The noise was activated
between licks 75–101. The following times were recorded: time to
first lick, time to complete licks 50–75 (before noise onset: A
period) and time to complete licks 76–101 (after noise onset: B
period). The suppression ratio was calculated as A/(A+B).
Drug Administration Schedule
Valproic acid sodium salt (Sigma-Aldrich, Canada) in 0.9%
NaCl was injected intraperitoneally (i.p) at 200 mg/kg, twice daily
for 14 days [19]. Behavioral testing started 20 hours after the last
injection (LI sessions were between injections), using independent
cohorts for each test and for microarrays, Western blotting, and
immunohistochemistry. Mice for tissue analysis were killed 20
hours after the last valproate injection, either by cervical
dislocation, or anaesthetized with pentobarbital.
Preparation of Total RNA
Gross brain dissections were performed to obtain brain stem
(BS), frontal cortex (FC), hippocampus (HIP), and striatum (STR)
samples, from which total RNA was extracted as described
previously [20]. Samples were mechanically homogenized and
lysed using TrizolH Reagent (Invitrogen, Carlsbad, CA). RNA was
precipitated with 70% ethanol, and purified and treated with
DNAase using the Absolutely RNA MiniprepH kit (Stratagene, La
Jolla, CA).
Target Preparation and Microarray Hybridization
Microarray hybridization and scanning were done at the
Ge´nome Que´bec Innovation Centre (Montreal, QC). RNA
samples were quantified using the NanoDrop ND-1000 UV-Vis
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA),
and evaluated using the Agilent Bioanalyzer 2100 (Agilent
Technologies, Santa Clara, CA). Complementary RNA (cRNA)
was amplified and biotinylated using the Illumina TotalPrep
Amplification Kit for 3–6 replicates within each treatment-
genotype combination and hybridized to MouseRef-8 v2.0
Expression BeadChips (.25,000 probes; Illumina, San Diego,
CA). BeadScan software (version 3, 2006) was used to identify
bead positions and to extract raw data.
Microarray Analysis
Each brain region was analyzed independently and identically.
A two-factor, two-level design was used, with the factors being
drug treatment and genotype. Raw array data were loaded into
the beadarray package (v1.10.0) of BioConductor [21]. Following
BASH analysis to remove spatial artifacts [22], data were pre-
processed using Edwards background correction [23] and
normalized using variance-stabilization (vsn package of BioCon-
ductor v3.8.0) [24]. A two-level, two-factor general linear model
was then fit to the pre-processed expression values from each bead
type using the limma package (v2.16.3) of BioConductor, followed
by an empirical Bayes moderation of the standard error and a false-
discovery rate (FDR) adjustment for multiple-testing. Genes were
selected at a 10% FDR threshold in any contrast. Both normalized
and pre-processed array data are available in GEO (GSE17735).
Data were visualized using unsupervised machine-learning [25].
The mean normalized signal intensities for each (tissue, genotype,
treatment) tuple were collated into a single matrix, with rows as
genes and columns as conditions. Rows were selected based on
sequential variance (0.1, 0.25, 0.5, 1.0) or signal intensity
(7,8,9,10,11,12) thresholds. This matrix was mean-centered and
root-mean-square-scaled, and then subjected to agglomerative
hierarchical clustering using complete linkage with Pearson’s
correlation as a distance metric. Heatmaps were generated in the
R statistical environment (v2.8.1) using the lattice (v0.17–20) and
lattice Extra (v0.5-4) packages. Functional analysis was performed
using the NIAID’s DAVID resource (v2008).
Verification of Microarray by Quantitative RT-PCR
The mRNA levels of Adar, Egr2, Slc40a1, Mrpl39, Slc6a12, Lcn2,
Arc, Dusp1, Purb, Cyr61, Igf1 and eiF4ebp2 were measured using
quantitative RT-PCR (qRT-PCR). cDNA was prepared using the
Omniscript Reverse Transcription kit (Qiagen, Valencia, CA), and
qRT-PCR was performed in quadruplicate using a reaction
volume of 50 mL on the ABI PRISM 7500 (Applied Biosystems
Inc., Foster City, CA). The qRT-PCR cycle consisted of activation
of AmpErase UNG (50uC, 2 min), Taq activation (95uC, 10 min),
40 cycles of denaturation (95uC, 15 sec), and elongation (60uC,
1 min) during which fluorescence was measured. Gene expression
was quantified using Gapdh and b-actin as endogenous controls for
normalization. All assays were from ABI. Correlation between
microarray data (fold-change in log 2-space) and qRT-PCR data
(fold-change in log 2-space, normalized to Gapdh and b-actin;
expressed as relative normalized expression, RNE, values) was
analyzed in R (v2.9.1).
Western Blotting
Tissues were homogenized in RIPA buffer (Sigma-Aldrich).
After centrifugation at 10,000 g at 4uC for 20 min, the supernatant
Valproic Acid in Disc1-L100P Mutant Mice
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Figure 2. Chronic treatment with valproic acid between 10 and 12 weeks of age prevented the emergence of hyperactivity and PPI
deficits in Disc1-L100P mutants and had a delayed effect on LI. (a) Valproic acid prevented hyperactivity in Disc1-L100P mice, but had no
effect on locomotion of WT mice (n = 8215 per group) [F1,41 = 8.4, p,0.001 genotype; F1,41 = 12.5, p,0.001 drug treatment; F1,41 = 5.6, p,0.05 gene
6 drug interaction. (b) Valproic acid prevented PPI deficits in Disc1-L100P mice. ANOVA showed a significant main effect of genotype [F1,41 = 7.6,
p,0.01 genotype; F1,41 = 5.5, p,0.05 drug treatment; F2,82 = 4.4, p,0.05 pre-pulse intensity; F1,41 = 9.6, p,0.01 gene6drug interaction], #p,0.001
in comparison with vehicle-treated WT mice; *p,0.05, **p,0.01, ***p,0.001 in comparison with vehicle-treated Disc1-L100P. (c) Valproic acid did
not prevent disrupted LI in Disc1-L100P mice [F1,43 = 51.1, p,0.001 genotype; F1,43 = 43.0 p,0.001 pre-exposure, and F1,43 = 33.5, p,0.001 genotype
6pre-exposure]. The eight experimental groups did not differ in A periods (all p.0.05, overall mean A period = 7.2 sec).#p,0.001 non-pre-exposed
Valproic Acid in Disc1-L100P Mutant Mice
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was extracted and protein concentrations were measured by
Bradford assay. Aliquots of protein extract (20–40 mg) were boiled
with Laemmli sample buffer, separated by 10–15% SDS-PAGE,
and transferred to PVDF membranes (Life Sciences). Blots were
immunostained overnight at 4uC with antibodies from Santa Cruz
Biotechnology: rat anti-LCN2 monoclonal (1:1000), rabbit anti-
Dusp1 polyclonal (1:1000), goat anti-Cyr61 polyclonal (1:1000),
and rabbit b-actin polyclonal (1:2000). Immune complexes were
detected using appropriate peroxidase-conjugated secondary
antibodies and a chemiluminescent reagent (ThermoScientific).
Immunohistochemistry
After pentobarbital anesthesia (120 mg/kg), mice were perfused
transcardially with 4% periodate-lysine-paraformaldehyde at 4uC.
Paraffin-embedded brain was cut into 5 mm thick sagittal sections,
de-paraffined with xylene and rehydrated with ethanol. After
blocking with Dako, the sections were incubated with primary
antibodies overnight (rabbit anti-ki67, Lab Vision, 1:200), anti-
neuronal nuclear protein (anti-NeuN, Chemicon, 1:200), or anti-
glial fibrillary acidic protein (anti-GFAP, COVANCE, 1:200),
followed by incubation with secondary antibody (goat anti-rabbit
IgG, Vector Labs, 1:200) and tertiary antibody (ABC, Vector labs,
1:50). DAB color development was followed by scanning (Aperio
Scanner). Apoptosis was assessed by TUNEL assay (Roche
Applied Science) following the manufacturer’s protocol. Cells
were counted using Aperio ImageScope software. At least four
animals per condition (genotype, drug) were used, and a total of
four sections per animal were analyzed.
Confocal Microscopy
After pentobarbital anesthesia and perfusion as above, whole
brain was immersed in 4% PFA for 24 hours, and 100 mm sagittal
slices were cut on a vibratome. Next, slices were immersed in 4%
BSA, 0.1% Triton-X 100, PBS solution for 15 minutes. Primary
antibodies (rabbit anti-LCN2 polyclonal, Santa Cruz Biotechnol-
ogy, 1:100) and mouse anti-GFAP (1:250) were incubated with
free-floating slices for 48 hours at 4uC. Slices were washed
3610 minutes in blocking-permeabilizing solution and incubated
with secondary antibodies (rabbit LCN2-CY5, 1:200 or mouse
GFAP-CY2, 1:200) for 2 hours at 20uC. Following incubation,
slices were washed again (3610 minutes) and mounted on glass
slides. For quantitative studies 3–5 mice per genotype and 4 slices
per mouse were examined (Zeiss LSM 510 confocal microscope).
All images were acquired with fixed exposure settings and analysed
using Nikon EZ-C1 FreeViewer v3.9.
Statistical Analysis
The effects of the Disc1-L100P mutation, age, valproate
treatment and Lcn2 deletion on mouse behaviors, cell counts,
and mRNA or protein levels were evaluated by ANOVA or
unpaired t-test. Because there were no significant sex effects, data
for both sexes were combined. Significant main effects or
interactions were followed by the Fisher’s least significance
difference (LSD) post-hoc test with significance set at p,0.05.
Results
Disc1-L100P Mice Behave Abnormally at 12 but not at 8
Weeks of Age
We assessed behavior of Disc1-L100P mutants at 8 weeks of age,
when PPI and LI normally develops [26,27,28], and later in
adulthood (12 weeks of age). We focused on behaviors relevant to
schizophrenia: hyperactivity, PPI, and LI [29]. Disc1-L100P
mutants were hyperactive at 12 but not 8 weeks of age compared
to WT mice (Figure 1a). A mild PPI deficit in 8 week-old Disc1-
L100P mice became more pronounced at 12 weeks (Figure 1b).
Disc1-L100P mice had normal Acoustic Startle Response (ASR) at
8 weeks of age, which decreased significantly by 12 weeks of age
(Figure 1c). Similarly, young adult Disc1-L100P mutant mice
showed LI, but had disrupted LI at 12 weeks of age, whereas WT
mice showed robust LI at both ages (Figure 1d).
Valproic Acid Prevented Schizophrenia-related Behavior
in Disc1-L100P Mice
Valproic acid treatment between 10 and 12 weeks of age
prevented hyperactivity, PPI deficits and ameliorated ASR, but
did not immediately correct LI deficits in Disc1-L100P mice
(Figure 2a–c and Table S1). All behaviours in valproic acid-
treated Disc1-L100P mice were comparable with WT mice, three
weeks after the last dose of valproic acid (Figure 2d–f). LI actually
improved in the three weeks after valproic acid treatment stopped.
These data show that valproic acid treatment had lasting effects on
behavior, even after the medication had been discontinued.
Transcriptomic Analysis
The Disc1-L100P mutation had the most pronounced effect on
gene expression in the hippocampus (61 genes), with 13 genes
showing altered expression in brain stem, but no changes in gene
expression in striatum or frontal cortex (Table 1 and Figure 3a).
Functional annotation of genes in the hippocampus revealed that
most are involved in cell proliferation (23%) and cytoskeleton/cell
shape (15%). Valproic acid significantly altered expression of 3
genes in hippocampus (Hist1h1c, Hist1h2be and Clcn2) and 2 genes
in striatum (Egr2 and Fosb). Among 61 genes altered by the Disc1-
L100P mutation, valproate corrected the expression of 13 genes
(21.3%) in hippocampus and Lcn2 in the brain stem. Expression of
14 genes was changed only in valproate-treated Disc1-L100P
mutants. The specific genes are listed in Tables S2-S6.
(NPE) in comparison with pre-exposed (PE) vehicle-treated WT to the conditioned stimulus (CS); **p,0.01; ***p,0.001 NPE in comparison with PE
animals within each genotype and drug treatment. (d-g) Valproic acid had lasting effects on behavior in Disc1-L100P mutants 3 weeks after the last
dose. (d) Valproic acid-treated Disc1-L100P and WT mice had similar locomotion, whereas vehicle-treated Disc1-L100P mutants were hyperactive in
comparison with vehicle-treated WT mice; *p,0.05 vs. vehicle-treated WT mice; *p,0.05 vs. vehicle-treated Disc1-L100P mice. (e) Valproic acid
prevention of PPI deficits in Disc1-L100P mice persisted 3 weeks after drug treatment ended [F1,40 = 5.7, p,0.05] as compared with vehicle-treated
Disc1-L100P mutants (p,0.05 at 69 dB and 81 dB; p,0.01 at 73 dB). In contrast, vehicle-treated Disc1-L100P mice showed PPI deficits [F1,40 = 5.54,
p,0.05] in comparison with vehicle-treated WT animals at all three pre-pulses (p,0.05 at 69 and 73 dB, p,0.01 at 81 dB). #p,0.05, ##p,0.01 in
comparison with vehicle-treated WT mice; *p,0.05; **p,0.01 in comparison with vehicle-treated Disc1-L100P mice. (f) Disc1-L100P mice treated with
valproic acid developed LI three weeks after treatment had stopped. Valproic acid-treated Disc1-L100P mice showed LI (p,0.01), similar to vehicle-
and valproic acid-treated WT mice (p,0.001 and p,0.01, respectively), but no LI in vehicle-treated Disc1-L100P mice (p.0.05). #p,0.001 in
comparison with vehicle-treated WT mice; **p,0.01; ***p,0.001 NPE in comparison with PE animals within each genotype and drug treatment.
ANOVA detected a significant effect of genotype [F1,43 = 12.8, p,0.001], drug treatment [F1,43 = 15.2 p,0.001], pre-exposure [F1,43 = 47.9 p,0.001]
and gene6drug6pre-exposure interactions [F1,43 = 6.1, p,0.05]. There was no difference in A periods among the eight experimental groups (all
p.0.05, overall mean A period= 8.1 sec).
doi:10.1371/journal.pone.0051562.g002
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Figure 3. Gene expression changes induced by the Disc1-L100P mutation and by treatment with valproic acid. (a) Heatmap showing
expression microarray results. Columns indicate individual genes, rows individual tuples (brain region, genotype, treatment). The color legend along
the bottom indicates the scaled signal intensity, with blue indicating high abundance. The colored boxes at right indicate, from left to right: the brain
region (red - striatum, blue - hippocampus, green - frontal cortex, yellow - brain stem), treatment (purple - valproic acid, white - vehicle), and
genotype (orange - Disc1-L100P, white - WT). BS - brain stem, FC - frontal cortex, HIP – hippocampus, STR - striatum. d1v - valproate-treated Disc1-
L100P mutants; d1c - vehicle-treated Disc1-L100P mutants; wtv - valproate-treated WT; wtc - vehicle-treated WT. (b) Validation of array results: Arc,
Egr2, Dusp1, Purb, Slc40a1, Adar, Mrpl39, Slc6a12, Lcn2, Igf1, EiF4ebp2 and Cyr61 transcripts were analyzed by RT-qPCR. Coefficients refer to either the
Valproic Acid in Disc1-L100P Mutant Mice
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Verification of Gene Expression by qRT-PCR
We used qRT-PCR to validate mRNA levels of genes for which:
(1) the effect of Disc1-L100P mutation was accompanied by the
opposite effect of valproic acid (genotype6 drug interaction) on
gene expression (Arc, Purb, Egr2, Dusp1, Slc40a1, Mrpl39, and Igf1),
(2) Disc1-L100P mutation alone had a significant effect on
expression (Slc6a12, Adar, Lcn2 and EiF4ebp2), and (3) genotype
6 drug interaction had a significant effect on expression (Cyr61).
Correlation analysis of microarray and qRT-PCR data validated
7/12 genes (Egr2, Slc40a1, Arc, Dusp1, Cyr61, Lcn2 and Slc6a12).
We obtained an overall validation rate of 0.6 (Figure 3b;
p = 0.037). The strongest candidate transcript was Lcn2
(Figure 3c), and Lcn2 protein levels were consistent with qRT-
PCR (Figure 3d–e). In particular, there was more Lcn2 brainstem
mRNA in Disc1-L100P mutants (p,0.05) that was normalized by
valproic acid.
Valproic Acid Corrected Increased Cell Proliferation in
Disc1-L100P Mutants
Given that DISC1 [4,5,6] and LCN2 [30] are both involved in
cell proliferation and that cell proliferation was the largest
functional category of altered transcripts (23%), we performed
immunohistochemistry on the cell proliferation marker Ki67 in
vehicle/valproic acid-treated Disc1-L100P and WT mice. As
shown in Figure 4a–b, vehicle-treated Disc1-L100P mutants had
more Ki67+ cells in olfactory bulbs (OB), rostral migratory stream
(RMS), and subventricular zone (SVZ), but not sub-granular zone
(SGZ) of hippocampus. These are the main areas for adult
neurogenesis [31]. Valproic acid no effect on Ki67+ cell counts in
WT mice.
Disc1-L100P Mutation Increased Glia but not Neurons in
SVZ
To identify the proliferating cells in Disc1-L100P mutants, we
performed immunohistochemistry with antibodies against neuro-
nal nuclear protein (NeuN) and glial fibrillary acidic protein
(GFAP). As shown in Figure 2c–d, there was a significant increase
in GFAP-positive cells in OB, RMS and SVZ in Disc1-L100P
mutants compared to WT mice but not in the hippocampus. Most
post-mortem studies in schizophrenia report no or minimal gliosis
[32], but some find gliosis in periventricular structures [33]. There
was no difference in the number of NeuN-positive cells in all brain
areas examined between the genotypes. We performed TUNEL
staining to assess cell death and found no differences between
Disc1-L100P and WT littermates. We also assessed cell pro-
liferation in young animals and did not find significant differences
between genotypes in the brain regions studied (Table S7).
Genetic Deletion of Lcn2 Corrected Excess GFAP+ Cells
and Normalized Behavior in Disc1-L100P Mutant Mice
We sought to assess the role of Lcn2 in mediating excess glial
cells and schizophrenia-related behavior by crossing mice that lack
both alleles of Lcn2 to either WT mice or Disc1-L100P mutants
[11,17]. LCN2 is an autocrine mediator of reactive astrocytosis
[34], which could be related to glial proliferation. Immunostaining
with LCN2 and GFAP antibodies revealed their co-expression in
OB, RMS, SVZ, cortex, hippocampus, and brain stem (Figure 5a).
The expression levels of the two genes were positively correlated
(r = 0.53, p,0.01) (Figure 5b). Disc1-L100P mutation increased
LCN2 and GFAP proteins in the SVZ (Figure 5c–d) as well as in
OB, RMS but not in the subgranular zone (SGZ). Genetic
inactivation of Lcn2 reduced the excess GFAP+ cells in SVZ
(Figure 5c–d), OB and RMS with no effect in SGZ in Disc1-L100P
mutant mice (Table S8). Finally, we assessed effect of genetic
inactivation of Lcn2 on schizophrenia-related behaviors. Ablation
of both copies of Lcn2 normalized locomotion, PPI, LI and ASR
abnormalities of Disc1-L100P mutants to the level of WT control
mice (Figure 5e–g).
Discussion
Our results show that: (1) abnormal behaviors in Disc1-L100P
mutant mice are present at 12 weeks but not 8 weeks of age; (2)
treatment with valproic acid prevented the emergence of
abnormal behaviors in Disc1-L100P mutants; (3) 23% of
transcripts altered in Disc1-L100P mice are implicated in cell
proliferation, including Lcn2; (4) there were more glial cells in the
SVZ, RMS and OB but not in SGZ of Disc1-L100P, which was
corrected by valproic acid; (5) genetic inactivation of Lcn2
corrected excess glial cells and schizophrenia-related behavior in
Disc1-L100P mutants (Figure 6). We have identified a novel
function for Lcn2 as a regulator of glial proliferation in the SVZ
and of behaviors relevant to schizophrenia.
An important question about the pathophysiology of schizo-
phrenia is why the psychotic symptoms emerge in the third decade
of life, despite high heritability and the presence of premorbid
abnormalities in early childhood [35]. Longitudinal magnetic
resonance imaging (MRI) studies reveal progressive structural
brain changes prior to the first episode of psychosis [36]. However,
it remains unknown whether these premorbid structural abnor-
malities can be prevented by prophylactic early intervention.
genotype-drug interaction term or the genotype term in ANOVA analyses. For microarrays, this analysis was performed using the fold-change
magnitude in log 2-space, for RT-qPCR, RNE values (log 2-based fold changes in mRNA quantity, normalized to Gapdh and b-actin levels). We
obtained an overall validation rate of 0.60 (P = 0.037). r, Pearson correlation factor. (c-e) Elevated Lcn2 (Lipocalin 2) expression in Disc1-L100P mutant
mice normalized by valproic acid treatment. (c) Lcn2 mRNA levels assessed by qRT-PCR (n = 526 per group). RNE values are relative to GAPDH and b-
actin. ANOVA detected a significant effect of genotype [F1,15 = 18.4, p,0.001], drug [F1,15 = 20.6, p,0.001] and gene6drug interaction [F1,15 = 18.2,
p,0.001] on Lcn2 expression. (d) Protein levels in representative Western blots are shown, probed with an antibodies against LCN2 and b-actin as
a loading control in extracts of brain stem isolated from vehicle- and valproate-treated Disc1-L100P and WT mice (n = 627 per group). (e)
Densitometric analysis to quantify the relative intensity of LCN2-immunoreactive bands relative to b-actin. ANOVA found a significant effect of
genotype [F1,20 = 31.4, p,0.001], drug [F1,20 = 21.9, p,0.001] and their interaction [F1,20 = 25.9, p,0.001] on LCN2 protein levels. *p,0.05 in
comparison with vehicle-treated WT; #p,0.05 in comparison with vehicle-treated Disc1-L100P mutants. See also Supplementary Tables S2–6.
doi:10.1371/journal.pone.0051562.g003
Table 1. The number of unique Illumina beads identified as
differentially expressed in each of the three conditions and
four brain regions.
Brain Region Valproate DISC1-L100P Interaction
Brain stem 0 13 2
Frontal cortex 0 0 2
Striatum 2 0 0
Hippocampus 3 61 30
doi:10.1371/journal.pone.0051562.t001
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Many schizophrenia patients have a prodromal period [1,37] of
social and functional decline [38], that provides an opportunity for
early intervention.
pWe have chosen to investigate the potential for valproic acid to
prevent the emergence of behavioral abnormalities in the Disc1-
L100P mouse model for several reasons. First, valproic acid is
already approved for use in teenagers as a mood stabilizer and
anticonvulsant [16,39]. 15 Second, schizophrenia is caused by
multiple factors that interact at many biological levels [40], so
improved treatment may have to target multiple mechanisms [41].
Valproic acid is a drug with many pharmacological actions
[16,42,43,44,45] and targets, including GABA transaminase,
voltage-gated sodium channels, glycogen synthase kinase (GSK)-
3, and histone deacetylases (HDACs) [16]. Thus, it was used as
a screen to test if early intervention in an animal model for
schizophrenia is feasible. Finally, we chose not to test antipsychotic
medications because clinical trials during the prodrome of
schizophrenia showed limited benefit [46].
To our knowledge, this is the first report of delayed onset of
schizophrenia-related behaviors in a genetic animal model of
schizophrenia. However, adolescent onset of schizophrenia-related
behaviors has also been observed with prenatal immune activation
by polyinosinic–polycytidilic acid (poly I:C) [47], and risperidone
pre-treatment can prevent brain and behavioral abnormalities if
administered in adolescence [48]. The beneficial effects of valproic
acid on Disc1-L100P mice are similar to its efficacy in other mouse
models of schizophrenia [19,49,50]. Importantly, we found that
chronic valproic acid treatment prevented schizophrenia-related
behaviors for three weeks after the last dose. Thus, we argue that
valproic acid treatment may have altered brain development,
rather than just having acute effects, which represents a new
paradigm for preventive treatments [51].
Genome-wide expression profiling identified large effects of the
Disc1-L100P mutation in the hippocampus, an area with high
DISC1 expression [52]; smaller but still significant effects were
also seen in the brain stem, consistent with a wide-ranging DISC1
Figure 4. Increased GFAP+ cell proliferation in Disc1-L100P mutants normalized by valproic acid. (a) Representative examples of brain
sections from olfactory bulb (OB), rostral migratory stream (RMS), subventricular zone (SVZ), and subgranular zone (SGZ) of the hippocampus of
vehicle-treated (top) or valproate-treated (bottom) WT and Disc1-L100P mice, immunostained for ki67 (dark brown). All images were taken at 106
magnification. (b) Quantitative analysis of the number of ki67+ nuclei in OB, RMS, SVZ and SGZ in all gene and drug conditions. OB: There was
a significant effect of genotype [F1,62 = 18.23; p,0.01]; drug [F1,62 = 18.9; p,0.01] and gene6drug interactions [F1,62 = 19,14; p,0.01]. RMS: There
was an effect of genotype [F1,62 = 17.38, p,0.01]; drug [F1,62 = 28.47, p,0.001] and their interaction [F1,62 = 15.71, p,0.05]. SVZ: There was
a significant effect of genotype [F1,62 = 28.54, p,0.01]; drug [F1,62 = 16.28; p,0.05] and their interactions [F1,62 = 16.54, p,0.01]. ANOVA did not detect
an effect of genotype and/or drug treatment on ki67+ cells in SGZ (all p.0.05). The number of ki67+ cells were expressed as the number of cells per
1 mm2 using Aperio Image Scope. *p,0.05; **p,0.01 in comparison with vehicle-treated WT mice; #p,0.01 in comparison with vehicle-treated
Disc1-L100P mice; Veh – vehicle; Val – valproate; n = 4 sections per animal from 4–6 mice; (c) Increased GFAP+ cells in OB, RMS and SVZ but not in SGZ
of vehicle-treated Disc1-L100P mice as compared to WT, assessed by GFAP immunostaining (brown). All images were taken at 206magnification. (d)
Quantitative analysis of the number of GFAP+ nuclei in OB, RMS, SVZ and SGZ. ANOVA detected a significant effect of genotype in OB [F1,30 = 7.71;
p,0.01], RMS [F1,30 = 8.18, p,0.01], SVZ [F1,30 = 8.81, p,0.05] but not in SGZ [F1,30 = 0.39, p.0.05]. The number of GFAP
+ cells were expressed as
the number of cells per 1 mm2 using Aperio Image Scope. *p,0.05; **p,0.01 in comparison with WT mice. n = 4 sections per animal from 4–6 mice.
See also Supplementary Table S7.
doi:10.1371/journal.pone.0051562.g004
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Figure 5. LCN2 is co-expressed with GFAP in the brain and levels are associated with behavior in Disc1-L100P mice. (a) Co-expression
of LCN2 with GFAP in the mouse brain shown in confocal microscopic images of cortical slices stained with LCN2 and GFAP antibodies (206
magnification). (b) Correlation of LCN2 and GFAP levels in different brain areas, including olfactory bulbs, rostral migratory stream, subventricular
zone (SVZ), subgranular zone of hippocampus and cortex (n = 21). Levels of GFAP+ and LCN2+ staining were expressed as the intensity per 1 um2
using a computerized image analyzer (EZ-C1, gold v3.9, Nikon Corporation). (c-d) Genetic inactivation of Lcn2 corrected the increased number of
GFAP+ cells in SVZ of Disc1-L100P mutant mice. (c). Confocal images of slices of the SVZ probed with LCN2 and GFAP in 4 genotypes: wild-type (WT);
Disc1-L100P, Lcn2-KO and Disc1-L100P6 Lcn2-KO (n = 4 slices per mouse; 3–5 mice per genotype; 206magnification). (d). Quantitative analysis of
LCN2 and GFAP expression in SVZ in mice of 4 genotypes. *p,0.05; **p,0.01 in comparison with WT; unpaired t-test. (e-g). Genetic inhibition of Lcn2
corrected behavior in Disc1-L100P mutant mice, including hyperactivity, pre-pulse inhibition (PPI) and latent inhibition (LI). (e) Locomotor activity in
the open field in WT or Disc1-L100P mice carrying both Lcn2 alleles (WT) or missing both Lcn2 alleles (LCN2-KO). ANOVA with repeated measures
found a main effect of genotype [F3,43 = 11.4, p,0.001], testing interval [F5,215 = 137.4, p,0.001] and genotype 6 testing interval interaction
[F15,215 = 3.2, p,0.001]. Disc1-L100P mutants were hyperactive at all tested intervals (p,0.001 during the first 15 minutes, p,0.01 at 15–20 minutes
and p,0.05 at 20–30 minutes), whereas genetic ablation of Lcn2 rendered their activity the same as WT mice. n = 6217 mice per genotype. *p,0.05;
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functional network [53]. Valproic acid alone had minimal effects
on gene expression in hippocampus and striatum, consistent with
the limited behavioral effect on WT animals. As expected, valproic
acid affected expression of transcription factors (Egr2 and Fosb),
genes involved in epigenetic regulation (Hist1h1c and Hist1h2be)
and neuronal excitability (Clcn2) [16]. Valproate had broad
transcriptional effects in DISC1 mutants, correcting 21.3% of
altered gene expression in the hippocampus. Moreover, we
detected convergent effects of both Disc1-L100P and valproate
on expression of 14 genes, of which five are independently
associated with schizophrenia (Tables S2–6).
Glial cells are important in synaptic function, maturation and
elimination, and are thus a potential therapeutic target for brain
disorders [54]. Here, we describe for the first time, an association
of schizophrenia-related behavior in Disc1 mutant mice with
increased LCN2 and GFAP+ glial cells in the SVZ. We found
similar results with pharmacological inhibition (Figure 4a–d) and
genetic inactivation of Lcn2 (Figure 5c–d; Table S8). LCN2 is
a glycoprotein initially purified from neutrophils [55], that
transports fatty acids and iron, induces apoptosis, regulates innate
immunity [30], and is a pro-neoplastic factor [30]. LCN2 is
secreted by astrocytes [56] and over-expression in zebrafish
increased the number and activity of GFAP+ glial cells [34].
Furthermore, mild cognitive impairment is associated with higher
plasma LCN2 levels [57]. One possible connection between Disc1
and Lcn2 is the Rho-ROCK pathway, through which LCN2
modifies reactive astrocytes [34]. The Disc1-L100P mutation
decreased expression of three Rho-related genes (Cdc42ep2;
Arhgap24 and Rock2; Table S3).
There are several limitations of the work described here. A
recent study of the Disc1-L100P mice backcrossed onto the
C57BL/6JJcl strain did not show the same phenotype as the
original paper characterizing this mutant [11,58]. C57BL/6JJcl
was the original strain subject to ENU mutagenesis, but C57BL/6J
was the strain backcrossed before phenotyping in the original
report. Thus it is possible that genetic background could affect the
phenotype, and that the results of the cross to the Lcn2 knock-out
mice are not specific to inactivation of the Lcn2 gene. Previous
studies have found that the antipsychotics haloperidol [13] and
clozapine [11] corrected behavioural abnormalities in adult (week
12–16) Disc1-L100P mice, but did not assess effects on behaviour
when treatment was delivered earlier, nor whether the drug effects
persisted after treatment stopped, as was done in the current study.
Finally, the L100P (T334C) mutation is not a polymorphism in
humans associated with schizophrenia, so direct comparison
across species is not possible. However, the Disc1-L100P mutation
does provide general insights about the possible effects of DISC1
variants in humans.
In conclusion, the current study demonstrates that Disc1-L100P
mutant mice have a developmental onset of behavioral and
**p,0.01; ***p,0.001 in comparison with WT mice. (f) PPI deficit in Disc1-L100P mutants was normalized at all three pre-pulses by genetic ablation
of Lcn2. ANOVA with repeated measures found a main effect of genotype [F3,31 = 14.1, p,0.001], and pre-pulse intensities [F2,62 = 6.6, p,0.05].
n = 6211 mice per genotype. ***p,0.001 in comparison with WT mice (g) Deletion of Lcn2 in Disc1-L100P mutants also restored LI. ANOVA detected
a significant effect of genotype [F3,47 = 13.5; p,0.001], pre-exposure [F1,47 = 62.4; p,0.001] and their interaction [F3,47 = 9.9, p,0.001]. n = 628 per
experimental group. ***p,0.001 non-pre-exposed (NPE) in comparison with pre-exposed (PE) animals to the conditioned stimulus (CS) within each
genotype.
doi:10.1371/journal.pone.0051562.g005
Figure 6. Summary of results. Lcn2 levels correlate with GFAP in subventricular zone (SVZ) and these are in turn associated with abnormal PPI, an
endophenotype for schizophrenia in Disc1-L100P mice. The 3D quadratic surface graph illustrates surfaces fitted by a smoothing technique to the
average PPI, GFAP and Lcn2 intensity in SVZ data. The color spectrum (from green to brown) represents the GFAP and Lcn2 intensity data (from low
to high, respectively). Pearson correlation coefficients are: r =20.73; p,0.001 – for PPI and Lcn2; r =20.56; p,0.05 – for PPI and GFAP and r = 0.77,
p,0.001– for Lcn2 and GFAP (N= 16).
doi:10.1371/journal.pone.0051562.g006
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cellular abnormalities that parallels some clinical features of
schizophrenia. We have shown that glial proliferation is increased
by Disc1-L100P mutation and that early treatment with valproic
acid or by genetic inactivation of Lcn2 can rectify this abnormal
proliferation in conjunction with normalizing behavior. Future
experiments will investigate molecular mechanisms underlying the
functional association of DISC1 and LCN2 in the brain and the
potential for valproic acid as a treatment in prodromal patients.
LCN2 might also be useful as new biomarker for the prodromal
stage of schizophrenia and as a potential new therapeutic target.
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